{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:12:02Z","timestamp":1791479522868,"version":"4.3.4"},"reference-count":255,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["TKP2021-NKTA-47"],"award-info":[{"award-number":["TKP2021-NKTA-47"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["TKP2021-EGA-29"],"award-info":[{"award-number":["TKP2021-EGA-29"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["National Cardiovascular Laboratory Program (RRF-2.3.1-21-2022-00003)"],"award-info":[{"award-number":["National Cardiovascular Laboratory Program (RRF-2.3.1-21-2022-00003)"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["the EK\u00d6P-2024-9 New National Excellence Program of the Ministry for Culture"],"award-info":[{"award-number":["the EK\u00d6P-2024-9 New National Excellence Program of the Ministry for Culture"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["Innovation"],"award-info":[{"award-number":["Innovation"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European University for Well-Being","award":["101004093\/ EUniWell\/EAC-A02-2019 \/ EAC-A02-2019-1"],"award-info":[{"award-number":["101004093\/ EUniWell\/EAC-A02-2019 \/ EAC-A02-2019-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Difficult-to-treat rheumatoid arthritis (D2T RA) is an emerging challenge in aging populations, where disease persistence and therapeutic failure often reflect not only autoimmune dysregulation but also the cumulative effects of age-related biological changes across multiple organ systems. This review reframes D2T RA through the lens of geroscience, highlighting how immunosenescence, inflammaging, and organ system vulnerability converge to create a treatment-resistant disease phenotype. Age-associated alterations in adaptive and innate immunity\u2014such as diminished T cell diversity, impaired regulatory function, expansion of age-associated B cells, and heightened inflammasome activation\u2014closely intersect with the immunopathogenesis of RA. The potential contribution of clonal hematopoiesis of indeterminate potential (CHIP) to systemic inflammation and myeloid dysfunction is also discussed as a novel mechanistic link. In parallel, aging of the musculoskeletal system magnifies joint damage, sarcopenia, and pain sensitization. Furthermore, advancing age is also accompanied by multimorbidity, polypharmacy, and frailty, which in turn constrain therapeutic options and increase the risk of adverse events. We argue that D2T RA in the elderly should not be viewed in isolation, but as part of a broader syndemic of age-related diseases driven by shared inflammatory and metabolic pathways. This perspective calls for a shift toward integrated, individualized care strategies that balance efficacy, safety, and quality of life. Future directions include the development of age-adapted treatment guidelines, expanded inclusion of older adults in clinical trials, and the application of artificial intelligence and machine learning to predict high-risk trajectories and personalize management. A geroscience-informed approach offers the conceptual foundation to meet the growing complexity of RA care in aging populations.<\/jats:p>","DOI":"10.1007\/s11357-025-02049-y","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:33:25Z","timestamp":1766795605000},"page":"2153-2177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity"],"prefix":"10.1007","volume":"48","author":[{"given":"Andrea","family":"Lehoczki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Ungvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Szappanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Gunkl-T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"2049_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631\u20137. https:\/\/doi.org\/10.1136\/ard.2009.123919.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae544","author":"ZLM Hofman","year":"2024","unstructured":"Hofman ZLM, Roodenrijs NMT, Nikiphorou E, Kent AL, Nagy G, Welsing PMJ, et al. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn? Rheumatology (Oxford). 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae544.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80:31\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR6","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1093\/rheumatology\/keac114","volume":"61","author":"NMT Roodenrijs","year":"2022","unstructured":"Roodenrijs NMT, Welsing PMJ, van Roon J, Schoneveld JLM, van der Goes MC, Nagy G, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology (Oxford). 2022;61:3552\u201366. https:\/\/doi.org\/10.1093\/rheumatology\/keac114.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","volume":"81","author":"G Nagy","year":"2022","unstructured":"Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81:20\u201333. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220973.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR8","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1016\/S2665-9913(24)00340-0","volume":"7","author":"G Nagy","year":"2025","unstructured":"Nagy G, Gunkl-Toth L, Dorgo AM, McInnes IB. The concept of difficult-to-treat disease in rheumatology: where next? Lancet Rheumatol. 2025;7:e274\u201389. https:\/\/doi.org\/10.1016\/S2665-9913(24)00340-0.","journal-title":"Lancet Rheumatol"},{"key":"2049_CR9","doi-asserted-by":"crossref","unstructured":"Fekete M, Major D, Feher A, Fazekas-Pongor V, Lehoczki A. Geroscience and pathology: a new frontier in understanding age-related diseases. Pathol Oncol Res. 2024. 10.3389\/pore.2024.1611623.","DOI":"10.3389\/pore.2024.1611623"},{"key":"2049_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: characteristics and treatment considerations. Autoimmun Rev. 2020;19:102528. https:\/\/doi.org\/10.1016\/j.autrev.2020.102528.","journal-title":"Autoimmun Rev"},{"key":"2049_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-025-06242-8","volume":"25","author":"RK Sah","year":"2025","unstructured":"Sah RK, Dey AB, Chatterjee P, Chakrawarty A, Kumar U, Dwivedi SN, et al. Study of rheumatoid arthritis in older patients: a cross-sectional study. BMC Geriatr. 2025;25:564. https:\/\/doi.org\/10.1186\/s12877-025-06242-8.","journal-title":"BMC Geriatr"},{"key":"2049_CR12","doi-asserted-by":"publisher","unstructured":"Pavlov-Dolijanovic S, Bogojevic M, Nozica-Radulovic T, Radunovic G, Mujovic N. Elderly-onset rheumatoid arthritis: characteristics and treatment options. Medicina (Kaunas). 2023;59. https:\/\/doi.org\/10.3390\/medicina59101878","DOI":"10.3390\/medicina59101878"},{"key":"2049_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-022-00322-7","volume":"6","author":"M Kojima","year":"2022","unstructured":"Kojima M, Kawahito Y, Sugihara T, Kojima T, Harada R, Hirata S, et al. Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design. BMC Rheumatol. 2022;6:90. https:\/\/doi.org\/10.1186\/s41927-022-00322-7.","journal-title":"BMC Rheumatol"},{"key":"2049_CR14","doi-asserted-by":"publisher","unstructured":"Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G, whole ETFodoErftcmod-t-tra. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018;77:1705\u20131709. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213687","DOI":"10.1136\/annrheumdis-2018-213687"},{"key":"2049_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101422","volume":"71","author":"A Santoro","year":"2021","unstructured":"Santoro A, Bientinesi E, Monti D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev. 2021;71:101422. https:\/\/doi.org\/10.1016\/j.arr.2021.101422.","journal-title":"Ageing Res Rev"},{"key":"2049_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/art.43105","volume":"77","author":"CM Weyand","year":"2025","unstructured":"Weyand CM, Goronzy JJ. Immune aging in rheumatoid arthritis. Arthritis Rheumatol. 2025;77:792\u2013804. https:\/\/doi.org\/10.1002\/art.43105.","journal-title":"Arthritis Rheumatol"},{"key":"2049_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2174\/1874609808666150727110744","volume":"8","author":"P Chalan","year":"2015","unstructured":"Chalan P, van den Berg A, Kroesen BJ, Brouwer L, Boots A. Rheumatoid arthritis, immunosenescence and the hallmarks of aging. Curr Aging Sci. 2015;8:131\u201346. https:\/\/doi.org\/10.2174\/1874609808666150727110744.","journal-title":"Curr Aging Sci"},{"key":"2049_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12979-020-00178-w","volume":"17","author":"ME Bauer","year":"2020","unstructured":"Bauer ME. Accelerated immunosenescence in rheumatoid arthritis: impact on clinical progression. Immun Ageing. 2020;17:6. https:\/\/doi.org\/10.1186\/s12979-020-00178-w.","journal-title":"Immun Ageing"},{"key":"2049_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8:200. https:\/\/doi.org\/10.1038\/s41392-023-01451-2.","journal-title":"Signal Transduct Target Ther"},{"key":"2049_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00300","volume":"8","author":"J Fessler","year":"2017","unstructured":"Fessler J, Raicht A, Husic R, Ficjan A, Schwarz C, Duftner C, et al. Novel senescent regulatory T-cell subset with impaired suppressive function in rheumatoid arthritis. Front Immunol. 2017;8:300. https:\/\/doi.org\/10.3389\/fimmu.2017.00300.","journal-title":"Front Immunol"},{"key":"2049_CR21","doi-asserted-by":"publisher","first-page":"9203","DOI":"10.1073\/pnas.97.16.9203","volume":"97","author":"K Koetz","year":"2000","unstructured":"Koetz K, Bryl E, Spickschen K, O\u2019Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A. 2000;97:9203\u20138. https:\/\/doi.org\/10.1073\/pnas.97.16.9203.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2049_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.clim.2007.01.005","volume":"123","author":"M Thewissen","year":"2007","unstructured":"Thewissen M, Somers V, Venken K, Linsen L, van Paassen P, Geusens P, et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol. 2007;123:209\u201318. https:\/\/doi.org\/10.1016\/j.clim.2007.01.005.","journal-title":"Clin Immunol"},{"key":"2049_CR23","doi-asserted-by":"publisher","first-page":"R210","DOI":"10.1186\/ar766","volume":"5","author":"A Pawlik","year":"2003","unstructured":"Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, et al. The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther. 2003;5:R210-213. https:\/\/doi.org\/10.1186\/ar766.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.0105-2896.2005.00259.x","volume":"205","author":"RB Effros","year":"2005","unstructured":"Effros RB, Dagarag M, Spaulding C, Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev. 2005;205:147\u201357. https:\/\/doi.org\/10.1111\/j.0105-2896.2005.00259.x.","journal-title":"Immunol Rev"},{"key":"2049_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/art.1780400615","volume":"40","author":"PB Martens","year":"1997","unstructured":"Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997;40:1106\u201314. https:\/\/doi.org\/10.1002\/art.1780400615.","journal-title":"Arthritis Rheum"},{"key":"2049_CR26","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3899\/jrheum.091176","volume":"37","author":"M Scarsi","year":"2010","unstructured":"Scarsi M, Ziglioli T, Air\u00f2 P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol. 2010;37:911\u20136. https:\/\/doi.org\/10.3899\/jrheum.091176.","journal-title":"J Rheumatol"},{"key":"2049_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4110\/in.2016.16.6.322","volume":"16","author":"GH Lee","year":"2016","unstructured":"Lee GH, Lee WW. Unusual CD4(+)CD28(-) T cells and their pathogenic role in chronic inflammatory disorders. Immune Netw. 2016;16:322\u20139. https:\/\/doi.org\/10.4110\/in.2016.16.6.322.","journal-title":"Immune Netw"},{"key":"2049_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23188","volume":"34","author":"M Garcia-Chagollan","year":"2020","unstructured":"Garcia-Chagollan M, Ledezma-Lozano IY, Hernandez-Bello J, Sanchez-Hernandez PE, Gutierrez-Urena SR, Munoz-Valle JF. Expression patterns of CD28 and CTLA-4 in early, chronic, and untreated rheumatoid arthritis. J Clin Lab Anal. 2020;34:e23188. https:\/\/doi.org\/10.1002\/jcla.23188.","journal-title":"J Clin Lab Anal"},{"key":"2049_CR29","doi-asserted-by":"publisher","unstructured":"Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, Catanese JJ, Xie G, Stahl EA, Chen R, Alfredsson L, Amos CI, Ardlie KG, Consortium B, Barton A, Bowes J, Burtt NP, Chang M, Coblyn J, Costenbader KH, Criswell LA, Crusius JB, Cui J, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, et al. Genetic variants at CD28, PRDM1 and CD2\/CD58 are associated with rheumatoid arthritis risk. Nat Genet. 2009;41:1313\u20131318. https:\/\/doi.org\/10.1038\/ng.479","DOI":"10.1038\/ng.479"},{"key":"2049_CR30","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1172\/JCI118638","volume":"97","author":"D Schmidt","year":"1996","unstructured":"Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest. 1996;97:2027\u201337. https:\/\/doi.org\/10.1172\/JCI118638.","journal-title":"J Clin Invest"},{"key":"2049_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/art.1780380512","volume":"38","author":"PP Sfikakis","year":"1995","unstructured":"Sfikakis PP, Zografou A, Viglis V, Iniotaki-Theodoraki A, Piskontaki I, Tsokos GC, et al. CD28 expression on T cell subsets in vivo and CD28-mediated T cell response in vitro in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:649\u201354. https:\/\/doi.org\/10.1002\/art.1780380512.","journal-title":"Arthritis Rheum"},{"key":"2049_CR32","first-page":"96","volume":"80","author":"J Verwilghen","year":"1993","unstructured":"Verwilghen J, Corrigall V, Pope RM, Rodrigues R, Panayi GS. Expression and function of CD5 and CD28 in patients with rheumatoid arthritis. Immunology. 1993;80:96\u2013102.","journal-title":"Immunology"},{"key":"2049_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/cei\/uxac107","volume":"211","author":"CM Weyand","year":"2023","unstructured":"Weyand CM, Wu B, Huang T, Hu Z, Goronzy JJ. Mitochondria as disease-relevant organelles in rheumatoid arthritis. Clin Exp Immunol. 2023;211:208\u201323. https:\/\/doi.org\/10.1093\/cei\/uxac107.","journal-title":"Clin Exp Immunol"},{"key":"2049_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102947","volume":"137","author":"Q Liu","year":"2023","unstructured":"Liu Q, Zheng Y, Goronzy JJ, Weyand CM. T cell aging as a risk factor for autoimmunity. J Autoimmun. 2023;137:102947. https:\/\/doi.org\/10.1016\/j.jaut.2022.102947.","journal-title":"J Autoimmun"},{"key":"2049_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2022.867950","volume":"3","author":"TV Zhao","year":"2022","unstructured":"Zhao TV, Sato Y, Goronzy JJ, Weyand CM. T-cell aging-associated phenotypes in autoimmune disease. Front Aging. 2022;3:867950. https:\/\/doi.org\/10.3389\/fragi.2022.867950.","journal-title":"Front Aging"},{"key":"2049_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s42255-022-00585-x","volume":"4","author":"Z Hu","year":"2022","unstructured":"Hu Z, Zhao TV, Huang T, Ohtsuki S, Jin K, Goronzy IN, et al. The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient stress in synovial macrophages. Nat Metab. 2022;4:759\u201374. https:\/\/doi.org\/10.1038\/s42255-022-00585-x.","journal-title":"Nat Metab"},{"key":"2049_CR37","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41467-021-21242-z","volume":"12","author":"Z Ye","year":"2021","unstructured":"Ye Z, Shen Y, Jin K, Qiu J, Hu B, Jadhav RR, et al. Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation. Nat Commun. 2021;12:907. https:\/\/doi.org\/10.1038\/s41467-021-21242-z.","journal-title":"Nat Commun"},{"key":"2049_CR38","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41590-021-01065-2","volume":"22","author":"B Wu","year":"2021","unstructured":"Wu B, Zhao TV, Jin K, Hu Z, Abdel MP, Warrington KJ, et al. Mitochondrial aspartate regulates TNF biogenesis and autoimmune tissue inflammation. Nat Immunol. 2021;22:1551\u201362. https:\/\/doi.org\/10.1038\/s41590-021-01065-2.","journal-title":"Nat Immunol"},{"key":"2049_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","volume":"22","author":"CM Weyand","year":"2021","unstructured":"Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22:10\u20138. https:\/\/doi.org\/10.1038\/s41590-020-00816-x.","journal-title":"Nat Immunol"},{"key":"2049_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652771","volume":"12","author":"J Qiu","year":"2021","unstructured":"Qiu J, Wu B, Goodman SB, Berry GJ, Goronzy JJ, Weyand CM. Metabolic control of autoimmunity and tissue inflammation in rheumatoid arthritis. Front Immunol. 2021;12:652771. https:\/\/doi.org\/10.3389\/fimmu.2021.652771.","journal-title":"Front Immunol"},{"key":"2049_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.cmet.2020.10.025","volume":"32","author":"B Wu","year":"2020","unstructured":"Wu B, Qiu J, Zhao TV, Wang Y, Maeda T, Goronzy IN, et al. Succinyl-CoA ligase deficiency in pro-inflammatory and tissue-invasive T cells. Cell Metab. 2020;32:967\u201380. https:\/\/doi.org\/10.1016\/j.cmet.2020.10.025.","journal-title":"Cell Metab"},{"key":"2049_CR42","doi-asserted-by":"publisher","first-page":"2473741","DOI":"10.1080\/08916934.2025.2473741","volume":"58","author":"G De Benedittis","year":"2025","unstructured":"De Benedittis G, Latini A, Morgante C, Bonini C, Cela E, Kroegler B, et al. Alteration of telomere length and mtDNA copy number in interstitial lung disease associated with rheumatoid arthritis. Autoimmunity. 2025;58:2473741. https:\/\/doi.org\/10.1080\/08916934.2025.2473741.","journal-title":"Autoimmunity"},{"key":"2049_CR43","doi-asserted-by":"publisher","first-page":"1585895","DOI":"10.3389\/fimmu.2025.1585895","volume":"16","author":"L Feng","year":"2025","unstructured":"Feng L, Bai K, He L, Wang H, Zhang W. Transcriptomic insights into the mechanism of action of telomere-related biomarkers in rheumatoid arthritis. Front Immunol. 2025;16:1585895. https:\/\/doi.org\/10.3389\/fimmu.2025.1585895.","journal-title":"Front Immunol"},{"key":"2049_CR44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00393-016-0209-9","volume":"77","author":"YH Lee","year":"2018","unstructured":"Lee YH, Bae SC. Association between shortened telomere length and rheumatoid arthritis\u202f: a meta-analysis. Z Rheumatol. 2018;77:160\u20137. https:\/\/doi.org\/10.1007\/s00393-016-0209-9.","journal-title":"Z Rheumatol"},{"key":"2049_CR45","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3899\/jrheum.151115","volume":"43","author":"MJ Ormseth","year":"2016","unstructured":"Ormseth MJ, Solus JF, Oeser AM, Bian A, Gebretsadik T, Shintani A, et al. Telomere length and coronary atherosclerosis in rheumatoid arthritis. J Rheumatol. 2016;43:1469\u201374. https:\/\/doi.org\/10.3899\/jrheum.151115.","journal-title":"J Rheumatol"},{"key":"2049_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/ard.2006.059188","volume":"66","author":"SE Steer","year":"2007","unstructured":"Steer SE, Williams FM, Kato B, Gardner JP, Norman PJ, Hall MA, et al. Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration. Ann Rheum Dis. 2007;66:476\u201380. https:\/\/doi.org\/10.1136\/ard.2006.059188.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2478\/rir-2022-0021","volume":"3","author":"P Ruan","year":"2022","unstructured":"Ruan P, Wang S, Yang M, Wu H. The ABC-associated immunosenescence and lifestyle interventions in autoimmune disease. Rheumatol Immunol Res. 2022;3:128\u201335. https:\/\/doi.org\/10.2478\/rir-2022-0021.","journal-title":"Rheumatol Immunol Res"},{"key":"2049_CR48","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1136\/ard-2022-222605","volume":"81","author":"Y Qin","year":"2022","unstructured":"Qin Y, Cai ML, Jin HZ, Huang W, Zhu C, Bozec A, et al. Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-\u03b1-mediated ERK1\/2 and JAK-STAT1 pathways. Ann Rheum Dis. 2022;81:1504\u201314. https:\/\/doi.org\/10.1136\/ard-2022-222605.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2022.104533","volume":"377","author":"W Bao","year":"2022","unstructured":"Bao W, Xie M, Ye Y. Age-associated B cells indicate disease activity in rheumatoid arthritis. Cell Immunol. 2022;377:104533. https:\/\/doi.org\/10.1016\/j.cellimm.2022.104533.","journal-title":"Cell Immunol"},{"key":"2049_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nri.2016.151","volume":"17","author":"A Liston","year":"2017","unstructured":"Liston A, Masters SL. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat Rev Immunol. 2017;17:208\u201314. https:\/\/doi.org\/10.1038\/nri.2016.151.","journal-title":"Nat Rev Immunol"},{"key":"2049_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115518","volume":"165","author":"CD Cezar","year":"2025","unstructured":"Cezar CD, Scholl JN, Rabelo CF, Madruga MP, da Silva PL, Grun LK, et al. Accelerated T-cell senescence and persistent inflammation in older adults with rheumatoid arthritis. Int Immunopharmacol. 2025;165:115518. https:\/\/doi.org\/10.1016\/j.intimp.2025.115518.","journal-title":"Int Immunopharmacol"},{"key":"2049_CR52","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1101\/gad.353125.125","volume":"39","author":"J Gil","year":"2025","unstructured":"Gil J. The interplay between senescence, inflammation, and the immune system. Genes Dev. 2025;39:923\u20135. https:\/\/doi.org\/10.1101\/gad.353125.125.","journal-title":"Genes Dev"},{"key":"2049_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Coppe","year":"2010","unstructured":"Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99\u2013118. https:\/\/doi.org\/10.1146\/annurev-pathol-121808-102144.","journal-title":"Annu Rev Pathol"},{"key":"2049_CR54","doi-asserted-by":"crossref","unstructured":"Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123:966\u201372. 10.1172\/JCI64098 64098 [pii]\n.","DOI":"10.1172\/JCI64098"},{"key":"2049_CR55","doi-asserted-by":"crossref","unstructured":"Wiley CD, Velarde MC, Lecot P, Liu S, Sarnoski EA, Freund A, et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab. 2016;23:303\u201314. 10.1016\/j.cmet.2015.11.011 S1550-4131(15)00578-1 [pii].","DOI":"10.1016\/j.cmet.2015.11.011"},{"key":"2049_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000599","volume":"18","author":"N Basisty","year":"2020","unstructured":"Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 2020;18:e3000599. https:\/\/doi.org\/10.1371\/journal.pbio.3000599.","journal-title":"PLoS Biol"},{"key":"2049_CR57","doi-asserted-by":"publisher","unstructured":"Evans DS, Young D, Tanaka T, Basisty N, Bandinelli S, Ferrucci L, Campisi J, Schilling B. Proteomic analysis of the senescence-associated secretory phenotype: GDF-15, IGFBP-2, and cystatin-C are associated with multiple aging traits. J Gerontol A Biol Sci Med Sci. 2024;79. https:\/\/doi.org\/10.1093\/gerona\/glad265","DOI":"10.1093\/gerona\/glad265"},{"key":"2049_CR58","doi-asserted-by":"publisher","unstructured":"Wu X, Zhang M, Moon JS, Song EK, Abrams JC, van Dam LS, Sharpe O, Feser M, Moss L, Ho PP, Smith MH, Donlin LH, Buckner JH, James EA, Firestein GS, Okamoto Y, Lanz TV, Meffre E, Holers VM, Deane KD, Robinson WH. Senescent activated naive B cells promote anti-citrullinated antigen T cell responses and the transition to clinical rheumatoid arthritis. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.10.14.682430","DOI":"10.1101\/2025.10.14.682430"},{"key":"2049_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fimmu.2018.00095","volume":"9","author":"J Fessler","year":"2018","unstructured":"Fessler J, Husic R, Schwetz V, Lerchbaum E, Aberer F, Fasching P, et al. Senescent T-cells promote bone loss in rheumatoid arthritis. Front Immunol. 2018;9:95. https:\/\/doi.org\/10.3389\/fimmu.2018.00095.","journal-title":"Front Immunol"},{"key":"2049_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114164","volume":"149","author":"J Chen","year":"2025","unstructured":"Chen J, Xu D, Chen B, Jian S, Chen T, Wang W, et al. Senescent macrophages trigger a pro-inflammatory program and promote the progression of rheumatoid arthritis. Int Immunopharmacol. 2025;149:114164. https:\/\/doi.org\/10.1016\/j.intimp.2025.114164.","journal-title":"Int Immunopharmacol"},{"key":"2049_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-019-0169-4","volume":"16","author":"MJ Del Rey","year":"2019","unstructured":"Del Rey MJ, Valin A, Usategui A, Ergueta S, Martin E, Municio C, et al. Senescent synovial fibroblasts accumulate prematurely in rheumatoid arthritis tissues and display an enhanced inflammatory phenotype. Immun Ageing. 2019;16:29. https:\/\/doi.org\/10.1186\/s12979-019-0169-4.","journal-title":"Immun Ageing"},{"key":"2049_CR62","doi-asserted-by":"publisher","unstructured":"de Jong TA, Semmelink JF, Bolt JW, Grasso C, Hoebe RA, Krawczyk PM, van Baarsen LGM. Senolytic treatment to rescue hallmarks of senescence in lymph node fibroblasts from patients with rheumatoid arthritis: implications for premature aging and potential therapeutic intervention in early rheumatoid arthritis. Clin Exp Immunol. 2025;219. https:\/\/doi.org\/10.1093\/cei\/uxaf029","DOI":"10.1093\/cei\/uxaf029"},{"key":"2049_CR63","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11357-024-01374-y","volume":"47","author":"A Kallai","year":"2025","unstructured":"Kallai A, Ungvari Z, Fekete M, Maier AB, Mikala G, Andrikovics H, et al. Genomic instability and genetic heterogeneity in aging: insights from clonal hematopoiesis (CHIP), monoclonal gammopathy (MGUS), and monoclonal B-cell lymphocytosis (MBL). Geroscience. 2025;47:703\u201320. https:\/\/doi.org\/10.1007\/s11357-024-01374-y.","journal-title":"Geroscience"},{"key":"2049_CR64","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood.2021011320","volume":"138","author":"M Rossi","year":"2021","unstructured":"Rossi M, Meggendorfer M, Zampini M, Tettamanti M, Riva E, Travaglino E, et al. Clinical relevance of clonal hematopoiesis in persons aged >\/=80 years. Blood. 2021;138:2093\u2013105. https:\/\/doi.org\/10.1182\/blood.2021011320.","journal-title":"Blood"},{"key":"2049_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0107-2","volume":"8","author":"P Savola","year":"2018","unstructured":"Savola P, Lundgren S, Keranen MAI, Almusa H, Ellonen P, Leirisalo-Repo M, et al. Clonal hematopoiesis in patients with rheumatoid arthritis. Blood Cancer J. 2018;8:69. https:\/\/doi.org\/10.1038\/s41408-018-0107-2.","journal-title":"Blood Cancer J"},{"key":"2049_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt9846","volume":"11","author":"E Hiitola","year":"2025","unstructured":"Hiitola E, Korhonen J, Kokkonen H, Koskela J, Kankainen M, Alakuijala M, et al. Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes. Sci Adv. 2025;11:eadt9846. https:\/\/doi.org\/10.1126\/sciadv.adt9846.","journal-title":"Sci Adv"},{"key":"2049_CR67","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/joim.20080","volume":"297","author":"H Wu","year":"2025","unstructured":"Wu H, Wei J, Yu Y, Wang N, Tan X. Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases. J Intern Med. 2025;297:642\u201356. https:\/\/doi.org\/10.1111\/joim.20080.","journal-title":"J Intern Med"},{"key":"2049_CR68","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/art.42745","volume":"76","author":"R Bucala","year":"2024","unstructured":"Bucala R, Tsao BP. The emerging spectrum of somatic mutation in rheumatic disease: clonal hematopoiesis connects aging with giant cell arteritis. Arthritis Rheumatol. 2024;76:351\u20133. https:\/\/doi.org\/10.1002\/art.42745.","journal-title":"Arthritis Rheumatol"},{"key":"2049_CR69","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/ATVBAHA.122.318928","volume":"43","author":"N Akhiyat","year":"2023","unstructured":"Akhiyat N, Lasho T, Ganji M, Toya T, Shi CX, Chen X, et al. Clonal hematopoiesis of indeterminate potential is associated with coronary microvascular dysfunction in early nonobstructive coronary artery disease. Arterioscler Thromb Vasc Biol. 2023;43:774\u201383. https:\/\/doi.org\/10.1161\/ATVBAHA.122.318928.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2049_CR70","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.121.037388","volume":"53","author":"R Bhattacharya","year":"2022","unstructured":"Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2022;53:788\u201397. https:\/\/doi.org\/10.1161\/STROKEAHA.121.037388.","journal-title":"Stroke"},{"key":"2049_CR71","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1161\/STROKEAHA.122.041416","volume":"54","author":"E Mayerhofer","year":"2023","unstructured":"Mayerhofer E, Strecker C, Becker H, Georgakis MK, Uddin MM, Hoffmann MM, et al. Prevalence and therapeutic implications of clonal hematopoiesis of indeterminate potential in young patients with stroke. Stroke. 2023;54:938\u201346. https:\/\/doi.org\/10.1161\/STROKEAHA.122.041416.","journal-title":"Stroke"},{"key":"2049_CR72","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.atherosclerosis.2020.02.008","volume":"297","author":"M Amoros-Perez","year":"2020","unstructured":"Amoros-Perez M, Fuster JJ. Clonal hematopoiesis driven by somatic mutations: a new player in atherosclerotic cardiovascular disease. Atherosclerosis. 2020;297:120\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.02.008.","journal-title":"Atherosclerosis"},{"key":"2049_CR73","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2021.1678","volume":"6","author":"R Bhattacharya","year":"2021","unstructured":"Bhattacharya R, Zekavat SM, Uddin MM, Pirruccello J, Niroula A, Gibson C, et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol. 2021;6:1069\u201377. https:\/\/doi.org\/10.1001\/jamacardio.2021.1678.","journal-title":"JAMA Cardiol"},{"key":"2049_CR74","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCRESAHA.117.312115","volume":"74","author":"JJ Fuster","year":"2018","unstructured":"Fuster JJ, Walsh K. Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. Circ Res. 2018;74:523\u201332. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.312115.","journal-title":"Circ Res"},{"key":"2049_CR75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180066","author":"O Oren","year":"2024","unstructured":"Oren O, Small AM, Libby P. Clonal hematopoiesis and atherosclerosis. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI180066.","journal-title":"J Clin Invest"},{"key":"2049_CR76","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.jacc.2023.03.401","volume":"76","author":"ED Gumuser","year":"2023","unstructured":"Gumuser ED, Schuermans A, Cho SMJ, Sporn ZA, Uddin MM, Paruchuri K, et al. Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2023;76:1996\u20132009. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.401.","journal-title":"J Am Coll Cardiol"},{"key":"2049_CR77","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1701719.","journal-title":"N Engl J Med"},{"key":"2049_CR78","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1161\/CIRCULATIONAHA.118.034392","volume":"138","author":"P Libby","year":"2018","unstructured":"Libby P, Ebert BL. CHIP (clonal hematopoiesis of indeterminate potential): potent and newly recognized contributor to cardiovascular risk. Circulation. 2018;138:666\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034392.","journal-title":"Circulation"},{"key":"2049_CR79","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1016\/j.cell.2024.05.003","volume":"79","author":"H Wang","year":"2024","unstructured":"Wang H, Divaris K, Pan B, Li X, Lim JH, Saha G, et al. Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss. Cell. 2024;79:3690-3711 e3619. https:\/\/doi.org\/10.1016\/j.cell.2024.05.003.","journal-title":"Cell"},{"key":"2049_CR80","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s44161-023-00281-3","volume":"2","author":"W Liu","year":"2023","unstructured":"Liu W, Yalcinkaya M, Maestre IF, Olszewska M, Ampomah PB, Heimlich JB, et al. Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis. Nat Cardiovasc Res. 2023;2:572\u201386. https:\/\/doi.org\/10.1038\/s44161-023-00281-3.","journal-title":"Nat Cardiovasc Res"},{"key":"2049_CR81","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamacardio.2020.2468","volume":"5","author":"WT Abplanalp","year":"2020","unstructured":"Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol. 2020;5:1170\u20135. https:\/\/doi.org\/10.1001\/jamacardio.2020.2468.","journal-title":"JAMA Cardiol"},{"key":"2049_CR82","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.123.065597","volume":"82","author":"AE Lin","year":"2024","unstructured":"Lin AE, Bapat AC, Xiao L, Niroula A, Ye J, Wong WJ, et al. Clonal hematopoiesis of indeterminate potential with loss of Tet2 enhances risk for atrial fibrillation through Nlrp3 inflammasome activation. Circulation. 2024;82:1419\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065597.","journal-title":"Circulation"},{"key":"2049_CR83","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood.2021011570","volume":"139","author":"LV Kovtonyuk","year":"2022","unstructured":"Kovtonyuk LV, Caiado F, Garcia-Martin S, Manz EM, Helbling P, Takizawa H, et al. IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice. Blood. 2022;139:44\u201358. https:\/\/doi.org\/10.1182\/blood.2021011570.","journal-title":"Blood"},{"key":"2049_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-025-02089-8","volume":"84","author":"F Sommer","year":"2025","unstructured":"Sommer F, Bernardes JP, Best L, Sommer N, Hamm J, Messner B, et al. Life-long microbiome rejuvenation improves intestinal barrier function and inflammaging in mice. Microbiome. 2025;84:91. https:\/\/doi.org\/10.1186\/s40168-025-02089-8.","journal-title":"Microbiome"},{"key":"2049_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13700","volume":"21","author":"LS Hohman","year":"2022","unstructured":"Hohman LS, Osborne LC. A gut-centric view of aging: do intestinal epithelial cells contribute to age-associated microbiota changes, inflammaging, and immunosenescence? Aging Cell. 2022;21:e13700. https:\/\/doi.org\/10.1111\/acel.13700.","journal-title":"Aging Cell"},{"key":"2049_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101596","volume":"77","author":"P Di Giosia","year":"2022","unstructured":"Di Giosia P, Stamerra CA, Giorgini P, Jamialahamdi T, Butler AE, Sahebkar A. The role of nutrition in inflammaging. Ageing Res Rev. 2022;77:101596. https:\/\/doi.org\/10.1016\/j.arr.2022.101596.","journal-title":"Ageing Res Rev"},{"key":"2049_CR87","doi-asserted-by":"publisher","first-page":"1452917","DOI":"10.3389\/fragi.2025.1452917","volume":"6","author":"D Gyriki","year":"2025","unstructured":"Gyriki D, Nikolaidis CG, Bezirtzoglou E, Voidarou C, Stavropoulou E, Tsigalou C. The gut microbiota and aging: interactions, implications, and interventions. Front Aging. 2025;6:1452917. https:\/\/doi.org\/10.3389\/fragi.2025.1452917.","journal-title":"Front Aging"},{"key":"2049_CR88","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x19844632","volume":"11","author":"R Bodkhe","year":"2019","unstructured":"Bodkhe R, Balakrishnan B, Taneja V. The role of microbiome in rheumatoid arthritis treatment. Ther Adv Musculoskelet Dis. 2019;11:1759720x19844632. https:\/\/doi.org\/10.1177\/1759720x19844632.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2049_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11092170","author":"D Coradduzza","year":"2023","unstructured":"Coradduzza D, Bo M, Congiargiu A, Azara E, De Miglio MR, Erre GL, et al. Decoding the microbiome\u2019s influence on rheumatoid arthritis. Microorganisms. 2023. https:\/\/doi.org\/10.3390\/microorganisms11092170.","journal-title":"Microorganisms"},{"key":"2049_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2024.101423","volume":"19","author":"E Liebing","year":"2025","unstructured":"Liebing E, Krug SM, Neurath MF, Siegmund B, Becker C. Wall of resilience: how the intestinal epithelium prevents inflammatory onslaught in the gut. Cell Mol Gastroenterol Hepatol. 2025;19:101423. https:\/\/doi.org\/10.1016\/j.jcmgh.2024.101423.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2049_CR91","doi-asserted-by":"publisher","first-page":"1584023","DOI":"10.3389\/fimmu.2025.1584023","volume":"16","author":"X Xie","year":"2025","unstructured":"Xie X, Chen X, Wang X, Wang S, Qi P. Dual regulatory effects of gut microbiota and their metabolites in rheumatoid arthritis: balancing pathogenic and protective mechanisms. Front Immunol. 2025;16:1584023. https:\/\/doi.org\/10.3389\/fimmu.2025.1584023.","journal-title":"Front Immunol"},{"key":"2049_CR92","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3389\/fphys.2020.00592","volume":"11","author":"A Zullo","year":"2020","unstructured":"Zullo A, Fleckenstein J, Schleip R, Hoppe K, Wearing S, Klingler W. Structural and functional changes in the coupling of fascial tissue, skeletal muscle, and nerves during aging. Front Physiol. 2020;11:592. https:\/\/doi.org\/10.3389\/fphys.2020.00592.","journal-title":"Front Physiol"},{"key":"2049_CR93","doi-asserted-by":"publisher","first-page":"592","DOI":"10.14336\/AD.2022.0831","volume":"14","author":"S Wakale","year":"2023","unstructured":"Wakale S, Wu X, Sonar Y, Sun A, Fan X, Crawford R, et al. How are aging and osteoarthritis related? Aging Dis. 2023;14:592\u2013604. https:\/\/doi.org\/10.14336\/AD.2022.0831.","journal-title":"Aging Dis"},{"key":"2049_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2024.112546","volume":"195","author":"L Wang","year":"2024","unstructured":"Wang L, Zhang J, Liang L, Song Z, Wang P, Ma L, et al. TDP-43 ameliorates aging-related cartilage degradation through preventing chondrocyte senescence. Exp Gerontol. 2024;195:112546. https:\/\/doi.org\/10.1016\/j.exger.2024.112546.","journal-title":"Exp Gerontol"},{"key":"2049_CR95","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41584-024-01136-2","volume":"20","author":"M Papatriantafyllou","year":"2024","unstructured":"Papatriantafyllou M. Mitophagy as a link between ECM stiffness and chondrocyte senescence. Nat Rev Rheumatol. 2024;20:455. https:\/\/doi.org\/10.1038\/s41584-024-01136-2.","journal-title":"Nat Rev Rheumatol"},{"key":"2049_CR96","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq1735","volume":"17","author":"Z Li","year":"2025","unstructured":"Li Z, Zhang W, Wei XY, Hu JZ, Hu X, Liu H, et al. TRIM15 drives chondrocyte senescence and osteoarthritis progression. Sci Transl Med. 2025;17:eadq1735. https:\/\/doi.org\/10.1126\/scitranslmed.adq1735.","journal-title":"Sci Transl Med"},{"key":"2049_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2025.112828","volume":"208","author":"K Huang","year":"2025","unstructured":"Huang K, Cai H. The role of chondrocyte senescence in osteoarthritis pathogenesis and therapeutic implications. Exp Gerontol. 2025;208:112828. https:\/\/doi.org\/10.1016\/j.exger.2025.112828.","journal-title":"Exp Gerontol"},{"issue":"1","key":"2049_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51746-3","volume":"15","author":"N Geng","year":"2024","unstructured":"Geng N, Fan M, Kuang B, Zhang F, Xian M, Deng L, et al. <article-title update=\"added\">10-hydroxy-2-decenoic acid prevents osteoarthritis by targeting aspartyl \u03b2 hydroxylase and inhibiting chondrocyte senescence in male mice preclinically. Nat Commun. 2024;15(1):7712. https:\/\/doi.org\/10.1038\/s41467-024-51746-3.","journal-title":"Nat Commun"},{"key":"2049_CR99","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1038\/s41467-023-40113-3","volume":"14","author":"WD Luo","year":"2023","unstructured":"Luo WD, Wang YP, Lv J, Liu Y, Qu YQ, Xu XF, et al. Age-related self-DNA accumulation may accelerate arthritis in rats and in human rheumatoid arthritis. Nat Commun. 2023;14:4394. https:\/\/doi.org\/10.1038\/s41467-023-40113-3.","journal-title":"Nat Commun"},{"key":"2049_CR100","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/916530","volume":"2013","author":"Y Li","year":"2013","unstructured":"Li Y, Wei X, Zhou J, Wei L. The age-related changes in cartilage and osteoarthritis. Biomed Res Int. 2013;2013:916530. https:\/\/doi.org\/10.1155\/2013\/916530.","journal-title":"Biomed Res Int"},{"key":"2049_CR101","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-023-00921-9","volume":"19","author":"JL Bennett","year":"2023","unstructured":"Bennett JL, Pratt AG, Dodds R, Sayer AA, Isaacs JD. Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis. Nat Rev Rheumatol. 2023;19:239\u201351. https:\/\/doi.org\/10.1038\/s41584-023-00921-9.","journal-title":"Nat Rev Rheumatol"},{"key":"2049_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2025.112729","volume":"203","author":"Q Ren","year":"2025","unstructured":"Ren Q, Ding K, Jiang W, Zhu W, Gao Y. Molecular crosstalk and potential causal mechanisms of rheumatoid arthritis and sarcopenia co-morbidity: a gene integration analysis. Exp Gerontol. 2025;203:112729. https:\/\/doi.org\/10.1016\/j.exger.2025.112729.","journal-title":"Exp Gerontol"},{"key":"2049_CR103","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/RHU.0000000000002194","volume":"31","author":"W Gumtorntip","year":"2025","unstructured":"Gumtorntip W, Phinyo P, Kasitanon N, Louthrenoo W. Prevalence and associated factors of sarcopenia in Thai rheumatoid arthritis patients: a cross-sectional study. J Clin Rheumatol. 2025;31:142\u20138. https:\/\/doi.org\/10.1097\/RHU.0000000000002194.","journal-title":"J Clin Rheumatol"},{"key":"2049_CR104","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ggi.14375","volume":"22","author":"M Suzuki","year":"2022","unstructured":"Suzuki M, Asai S, Sobue Y, Ohashi Y, Koshima H, Okui N, et al. Influence of frailty on patient global assessment in rheumatoid arthritis. Geriatr Gerontol Int. 2022;22:399\u2013404. https:\/\/doi.org\/10.1111\/ggi.14375.","journal-title":"Geriatr Gerontol Int"},{"key":"2049_CR105","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1007\/s10067-021-05744-1","volume":"40","author":"F Salaffi","year":"2021","unstructured":"Salaffi F, De Angelis R, Farah S, Carotti M, Di Carlo M. Frailty as a novel predictor of achieving comprehensive disease control (CDC) in rheumatoid arthritis. Clin Rheumatol. 2021;40:4869\u201377. https:\/\/doi.org\/10.1007\/s10067-021-05744-1.","journal-title":"Clin Rheumatol"},{"key":"2049_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105343","volume":"89","author":"RC Gao","year":"2022","unstructured":"Gao RC, Wu ZG, Wu ZZ, Hao M, Wu GC. Frailty in rheumatoid arthritis: a systematic review and meta-analysis. Joint Bone Spine. 2022;89:105343. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105343.","journal-title":"Joint Bone Spine"},{"key":"2049_CR107","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/acr2.11051","volume":"1","author":"JS Andrews","year":"2019","unstructured":"Andrews JS, Trupin L, Wysham KD, Hough CL, Yelin EH, Katz PP. The impact of frailty on changes in physical function and disease activity among adults with rheumatoid arthritis. ACR Open Rheumatol. 2019;1:366\u201372. https:\/\/doi.org\/10.1002\/acr2.11051.","journal-title":"ACR Open Rheumatol"},{"key":"2049_CR108","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s10067-023-06639-z","volume":"42","author":"Y Sobue","year":"2023","unstructured":"Sobue Y, Suzuki M, Ohashi Y, Koshima H, Okui N, Funahashi K, et al. Relationship between frailty and methotrexate discontinuation due to adverse events in rheumatoid arthritis patients. Clin Rheumatol. 2023;42:2069\u201377. https:\/\/doi.org\/10.1007\/s10067-023-06639-z.","journal-title":"Clin Rheumatol"},{"key":"2049_CR109","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/acr.25282","volume":"76","author":"N Singh","year":"2024","unstructured":"Singh N, Gold LS, Lee J, Wysham KD, Andrews JS, Makris UE, et al. Frailty and risk of serious infections in patients with rheumatoid arthritis treated with biologic or targeted-synthetic disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2024;76:627\u201335. https:\/\/doi.org\/10.1002\/acr.25282.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2049_CR110","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12929-021-00714-w","volume":"28","author":"T Ollewagen","year":"2021","unstructured":"Ollewagen T, Myburgh KH, van de Vyver M, Smith C. Rheumatoid cachexia: the underappreciated role of myoblast, macrophage and fibroblast interplay in the skeletal muscle niche. J Biomed Sci. 2021;28:15. https:\/\/doi.org\/10.1186\/s12929-021-00714-w.","journal-title":"J Biomed Sci"},{"key":"2049_CR111","doi-asserted-by":"publisher","DOI":"10.2196\/64456","volume":"14","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wu Q, Wang Y, Chen Q, Han S, Li B, et al. Systemic inflammation and disruption of the local microenvironment compromise muscle regeneration: critical pathogenesis of autoimmune-associated sarcopenia. Interact J Med Res. 2025;14:e64456. https:\/\/doi.org\/10.2196\/64456.","journal-title":"Interact J Med Res"},{"key":"2049_CR112","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00296-018-4028-y","volume":"38","author":"RJ Boutrup","year":"2018","unstructured":"Boutrup RJ, Farup J, Vissing K, Kjaer M, Mikkelsen UR. Skeletal muscle stem cell characteristics and myonuclei content in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int. 2018;38:1031\u201341. https:\/\/doi.org\/10.1007\/s00296-018-4028-y.","journal-title":"Rheumatol Int"},{"key":"2049_CR113","doi-asserted-by":"publisher","first-page":"1199031","DOI":"10.3389\/fphar.2023.1199031","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Li Y, Li J, Zhang Q, Wu J, Li X, et al. Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol. 2023;14:1199031. https:\/\/doi.org\/10.3389\/fphar.2023.1199031.","journal-title":"Front Pharmacol"},{"key":"2049_CR114","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mus.21280","volume":"39","author":"DB Fee","year":"2009","unstructured":"Fee DB, Kasarskis EJ. Myasthenia gravis associated with etanercept therapy. Muscle Nerve. 2009;39:866\u201370. https:\/\/doi.org\/10.1002\/mus.21280.","journal-title":"Muscle Nerve"},{"key":"2049_CR115","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00296-020-04587-4","volume":"40","author":"E Pelechas","year":"2020","unstructured":"Pelechas E, Memi T, Markatseli TE, Voulgari PV, Drosos AA. Adalimumab-induced myasthenia gravis: case-based review. Rheumatol Int. 2020;40:1891\u20134. https:\/\/doi.org\/10.1007\/s00296-020-04587-4.","journal-title":"Rheumatol Int"},{"key":"2049_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.576134","volume":"11","author":"F Motta","year":"2020","unstructured":"Motta F, Sica A, Selmi C. Frailty in rheumatic diseases. Front Immunol. 2020;11:576134. https:\/\/doi.org\/10.3389\/fimmu.2020.576134.","journal-title":"Front Immunol"},{"key":"2049_CR117","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2076328","volume":"2020","author":"Y Cao","year":"2020","unstructured":"Cao Y, Fan D, Yin Y. Pain mechanism in rheumatoid arthritis: from cytokines to central sensitization. Mediators Inflamm. 2020;2020:2076328. https:\/\/doi.org\/10.1155\/2020\/2076328.","journal-title":"Mediators Inflamm"},{"key":"2049_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103423","volume":"22","author":"P Sarzi-Puttini","year":"2023","unstructured":"Sarzi-Puttini P, Zen M, Arru F, Giorgi V, Choy EA. Residual pain in rheumatoid arthritis: is it a real problem? Autoimmun Rev. 2023;22:103423. https:\/\/doi.org\/10.1016\/j.autrev.2023.103423.","journal-title":"Autoimmun Rev"},{"key":"2049_CR119","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10067-025-07331-0","volume":"44","author":"S Perniola","year":"2025","unstructured":"Perniola S, Bruno D, Di Mario C, Campobasso D, Calabretta M, Gessi M, et al. Residual pain and fatigue are affected by disease perception in rheumatoid arthritis in sustained clinical and ultrasound remission. Clin Rheumatol. 2025;44:1019\u201329. https:\/\/doi.org\/10.1007\/s10067-025-07331-0.","journal-title":"Clin Rheumatol"},{"key":"2049_CR120","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5114\/reum\/189779","volume":"62","author":"G Motyl","year":"2024","unstructured":"Motyl G, Krupka WM, Maslinska M. The problem of residual pain in the assessment of rheumatoid arthritis activity. Reumatologia. 2024;62:176\u201386. https:\/\/doi.org\/10.5114\/reum\/189779.","journal-title":"Reumatologia"},{"key":"2049_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163566","author":"M Dey","year":"2021","unstructured":"Dey M, Parodis I, Nikiphorou E. Fatigue in systemic lupus erythematosus and rheumatoid arthritis: a comparison of mechanisms, measures and management. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10163566.","journal-title":"J Clin Med"},{"key":"2049_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1555089","volume":"12","author":"JM Nolla","year":"2025","unstructured":"Nolla JM, Valencia-Muntala L, Berbel-Arcobe L, Benavent D, Vidal-Montal P, Aguilar-Coll M, et al. Fatigue and associated factors in men with rheumatoid arthritis: a case-control study using the FACIT-F scale. Front Med (Lausanne). 2025;12:1555089. https:\/\/doi.org\/10.3389\/fmed.2025.1555089.","journal-title":"Front Med (Lausanne)"},{"key":"2049_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25579","author":"NV Chalupczak","year":"2025","unstructured":"Chalupczak NV, Aydemir B, Isaacs A, Muhammad LN, Song J, Reid KJ, et al. Sleep matters: exploring the link between sleep disturbances and fatigue in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2025. https:\/\/doi.org\/10.1002\/acr.25579.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2049_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2025.1534447","volume":"6","author":"KA Kozlowska","year":"2025","unstructured":"Kozlowska KA, Baczyk G. Sleep quality and fatigue level, clinical and demographic factors in women with rheumatoid arthritis. Front Glob Womens Health. 2025;6:1534447. https:\/\/doi.org\/10.3389\/fgwh.2025.1534447.","journal-title":"Front Glob Womens Health"},{"key":"2049_CR125","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00296-014-3196-7","volume":"35","author":"E Loza","year":"2015","unstructured":"Loza E, Lajas C, Andreu JL, Balsa A, Gonzalez-Alvaro I, Illera O, et al. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int. 2015;35:445\u201358. https:\/\/doi.org\/10.1007\/s00296-014-3196-7.","journal-title":"Rheumatol Int"},{"key":"2049_CR126","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.clinthera.2019.04.018","volume":"41","author":"JT Giles","year":"2019","unstructured":"Giles JT. Extra-articular manifestations and comorbidity in rheumatoid arthritis: potential impact of pre-rheumatoid arthritis prevention. Clin Ther. 2019;41:1246\u201355. https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.018.","journal-title":"Clin Ther"},{"key":"2049_CR127","doi-asserted-by":"publisher","first-page":"232","DOI":"10.12968\/bjcn.2022.27.5.232","volume":"27","author":"J Hill","year":"2022","unstructured":"Hill J, Harrison J, Christian D, Reed J, Clegg A, Duffield SJ, et al. The prevalence of comorbidity in rheumatoid arthritis: a systematic review and meta-analysis. Br J Community Nurs. 2022;27:232\u201341. https:\/\/doi.org\/10.12968\/bjcn.2022.27.5.232.","journal-title":"Br J Community Nurs"},{"key":"2049_CR128","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","volume":"62","author":"M Dey","year":"2023","unstructured":"Dey M, Nagy G, Nikiphorou E. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology (Oxford). 2023;62:1773\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keac584.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102925","volume":"21","author":"V Restivo","year":"2022","unstructured":"Restivo V, Candiloro S, Daidone M, Norrito R, Cataldi M, Minutolo G, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2022;21:102925. https:\/\/doi.org\/10.1016\/j.autrev.2021.102925.","journal-title":"Autoimmun Rev"},{"key":"2049_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/ar2383","volume":"10","author":"A Naranjo","year":"2008","unstructured":"Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10:R30. https:\/\/doi.org\/10.1186\/ar2383.","journal-title":"Arthritis Res Ther"},{"issue":"622\u2013628","key":"2049_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.07.010","volume":"166","author":"CS Crowson","year":"2013","unstructured":"Crowson CS, Liao KP, Davis JM 3rd, Solomon DH, Matteson EL, Knutson KL, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166(622\u2013628):e621. https:\/\/doi.org\/10.1016\/j.ahj.2013.07.010.","journal-title":"Am Heart J"},{"key":"2049_CR132","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis. 2017;76:17\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR133","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.2147\/IJGM.S490916","volume":"17","author":"S Tekeoglu","year":"2024","unstructured":"Tekeoglu S. Prevalence and risk factors of cardiovascular disease in rheumatoid arthritis patients: a comparative analysis of real-world data. Int J Gen Med. 2024;17:5859\u201368. https:\/\/doi.org\/10.2147\/IJGM.S490916.","journal-title":"Int J Gen Med"},{"key":"2049_CR134","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3899\/jrheum.2023-1078","volume":"51","author":"E Rydell","year":"2024","unstructured":"Rydell E, Jacobsson LTH, Turesson C. Circulating interleukin 17A and other inflammatory proteins may predict cardiovascular disease in early rheumatoid arthritis. J Rheumatol. 2024;51:752\u20138. https:\/\/doi.org\/10.3899\/jrheum.2023-1078.","journal-title":"J Rheumatol"},{"key":"2049_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103539","volume":"23","author":"Y Hajiesmaeili","year":"2024","unstructured":"Hajiesmaeili Y, Tamhankar P, Stranges S, Barra L. Factors associated with incident cardiovascular disease in patients with rheumatoid arthritis: a scoping review. Autoimmun Rev. 2024;23:103539. https:\/\/doi.org\/10.1016\/j.autrev.2024.103539.","journal-title":"Autoimmun Rev"},{"key":"2049_CR136","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-02157-5","author":"M Feng","year":"2024","unstructured":"Feng M, Meng F, Jia Y, Wang Y, Ji G, Gao C, et al. Exploration of risk factors for cardiovascular disease in patients with rheumatoid arthritis: a retrospective study. Inflammation. 2024. https:\/\/doi.org\/10.1007\/s10753-024-02157-5.","journal-title":"Inflammation"},{"key":"2049_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.601344","volume":"11","author":"N Mong","year":"2020","unstructured":"Mong N, Tarjanyi Z, Tothfalusi L, Bartykowszki A, Nagy AI, Szekely A, et al. Largely accelerated arterial aging in rheumatoid arthritis is associated with inflammatory activity and smoking in the early stage of the disease. Front Pharmacol. 2020;11:523962. https:\/\/doi.org\/10.3389\/fphar.2020.601344.","journal-title":"Front Pharmacol"},{"key":"2049_CR138","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jacbts.2023.12.003","volume":"9","author":"M Kumar","year":"2024","unstructured":"Kumar M, Yan P, Kuchel GA, Xu M. Cellular senescence as a targetable risk factor for cardiovascular diseases: therapeutic implications: JACC family series. JACC Basic Transl Sci. 2024;9:522\u201334. https:\/\/doi.org\/10.1016\/j.jacbts.2023.12.003.","journal-title":"JACC Basic Transl Sci"},{"key":"2049_CR139","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/CIRCRESAHA.118.312497","volume":"123","author":"W Zhang","year":"2018","unstructured":"Zhang W, Song M, Qu J, Liu GH. Epigenetic modifications in cardiovascular aging and diseases. Circ Res. 2018;123:773\u201386. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312497.","journal-title":"Circ Res"},{"key":"2049_CR140","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/JPR.S83653","volume":"9","author":"L Sharpe","year":"2016","unstructured":"Sharpe L. Psychosocial management of chronic pain in patients with rheumatoid arthritis: challenges and solutions. J Pain Res. 2016;9:137\u201346. https:\/\/doi.org\/10.2147\/JPR.S83653.","journal-title":"J Pain Res"},{"key":"2049_CR141","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/ar3306","volume":"13","author":"YC Lee","year":"2011","unstructured":"Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13:211. https:\/\/doi.org\/10.1186\/ar3306.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR142","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1097\/j.pain.0000000000002728","volume":"164","author":"Kasher M, Williams FMK, Freidin MB, Cherny SS, Malkin I, Livshits G, Group CIW","year":"2023","unstructured":"Kasher M, Williams FMK, Freidin MB, Cherny SS, Malkin I, Livshits G, Group CIW. Insights into the pleiotropic relationships between chronic back pain and inflammation-related musculoskeletal conditions: rheumatoid arthritis and osteoporotic abnormalities. Pain. 2023;164:e122\u201334. https:\/\/doi.org\/10.1097\/j.pain.0000000000002728.","journal-title":"Pain"},{"issue":"3","key":"2049_CR143","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/BOR.0000000000000929","volume":"35","author":"D Minhas","year":"2023","unstructured":"Minhas D, Murphy A, Clauw DJ. Fibromyalgia and centralized pain in the rheumatoid arthritis patient. Curr Opin Rheumatol. 2023;35(3):170\u20134. https:\/\/doi.org\/10.1097\/BOR.0000000000000929.","journal-title":"Curr Opin Rheumatol"},{"key":"2049_CR144","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40695-019-0047-4","volume":"5","author":"MG Chancay","year":"2019","unstructured":"Chancay MG, Guendsechadze SN, Blanco I. Types of pain and their psychosocial impact in women with rheumatoid arthritis. Womens Midlife Health. 2019;5:3. https:\/\/doi.org\/10.1186\/s40695-019-0047-4.","journal-title":"Womens Midlife Health"},{"key":"2049_CR145","doi-asserted-by":"publisher","first-page":"394","DOI":"10.31138\/mjr.33.4.394","volume":"33","author":"D Karokis","year":"2022","unstructured":"Karokis D, Karamanis D, Xesfingi S, Antonopoulos I, Politi E, Bounas A, et al. Anxiety, distress, and depression in elderly rheumatoid arthritis patients. Mediterr J Rheumatol. 2022;33:394\u2013406. https:\/\/doi.org\/10.31138\/mjr.33.4.394.","journal-title":"Mediterr J Rheumatol"},{"key":"2049_CR146","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9724371","volume":"2017","author":"J Sheng","year":"2017","unstructured":"Sheng J, Liu S, Wang Y, Cui R, Zhang X. The link between depression and chronic pain: neural mechanisms in the brain. Neural Plast. 2017;2017:9724371. https:\/\/doi.org\/10.1155\/2017\/9724371.","journal-title":"Neural Plast"},{"key":"2049_CR147","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-024-03432-4","volume":"27","author":"N Luciano","year":"2025","unstructured":"Luciano N, Barone E, Brunetta E, D\u2019Isanto A, De Santis M, Ceribelli A, et al. Obesity and fibromyalgia are associated with difficult-to-treat rheumatoid arthritis (D2T-RA) independent of age and gender. Arthritis Res Ther. 2025;27:2. https:\/\/doi.org\/10.1186\/s13075-024-03432-4.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR148","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrrheum.2014.64","volume":"10","author":"DA Walsh","year":"2014","unstructured":"Walsh DA, McWilliams DF. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10:581\u201392. https:\/\/doi.org\/10.1038\/nrrheum.2014.64.","journal-title":"Nat Rev Rheumatol"},{"key":"2049_CR149","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/15360288.2021.1973647","volume":"35","author":"JC Sanchez-Florez","year":"2021","unstructured":"Sanchez-Florez JC, Seija-Butnaru D, Valero EG, Acosta C, Amaya S. Pain management strategies in rheumatoid arthritis: a narrative review. J Pain Palliat Care Pharmacother. 2021;35:291\u20139. https:\/\/doi.org\/10.1080\/15360288.2021.1973647.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2049_CR150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008921.pub2","volume":"1","author":"BL Richards","year":"2012","unstructured":"Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1:CD008921. https:\/\/doi.org\/10.1002\/14651858.CD008921.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2049_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008922.pub2","author":"BL Richards","year":"2012","unstructured":"Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012. https:\/\/doi.org\/10.1002\/14651858.CD008922.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2049_CR152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008920.pub2","volume":"2011","author":"BL Richards","year":"2011","unstructured":"Richards BL, Whittle SL, Buchbinder R. Antidepressants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2011;2011:CD008920. https:\/\/doi.org\/10.1002\/14651858.CD008920.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2049_CR153","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-025-01184-x","volume":"27","author":"P Pham","year":"2025","unstructured":"Pham P, Lee YC. Non-pharmacological pain management of rheumatoid arthritis. Curr Rheumatol Rep. 2025;27:21. https:\/\/doi.org\/10.1007\/s11926-025-01184-x.","journal-title":"Curr Rheumatol Rep"},{"key":"2049_CR154","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jpain.2008.09.012","volume":"10","author":"MA Fitzcharles","year":"2009","unstructured":"Fitzcharles MA, DaCosta D, Ware MA, Shir Y. Patient barriers to pain management may contribute to poor pain control in rheumatoid arthritis. J Pain. 2009;10:300\u20135. https:\/\/doi.org\/10.1016\/j.jpain.2008.09.012.","journal-title":"J Pain"},{"key":"2049_CR155","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(14)61704-9.","journal-title":"Lancet"},{"issue":"6","key":"2049_CR156","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/1756-185X.12659","volume":"19","author":"C Downey","year":"2016","unstructured":"Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: a literature review. Int J Rheum Dis. 2016;19(6):536\u201350. https:\/\/doi.org\/10.1111\/1756-185X.12659.","journal-title":"Int J Rheum Dis"},{"key":"2049_CR157","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58:1755\u201366. https:\/\/doi.org\/10.1093\/rheumatology\/kez087.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR158","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s41927-025-00513-y","volume":"9","author":"L Tang","year":"2025","unstructured":"Tang L, Zhang L, Ding Z, Xu W, Liu Y, Yu Z. Association between hepatitis C virus infection and rheumatoid arthritis: a nationwide cross-sectional study. BMC Rheumatol. 2025;9:61. https:\/\/doi.org\/10.1186\/s41927-025-00513-y.","journal-title":"BMC Rheumatol"},{"key":"2049_CR159","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-020-02398-3","volume":"23","author":"JL Davignon","year":"2021","unstructured":"Davignon JL, Combe B, Cantagrel A. Cytomegalovirus infection: friend or foe in rheumatoid arthritis? Arthritis Res Ther. 2021;23:16. https:\/\/doi.org\/10.1186\/s13075-020-02398-3.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR160","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gastrohep.2021.01.007","volume":"44","author":"X Calvet","year":"2021","unstructured":"Calvet X, Carpio D, Rodriguez-Lago I, Garcia-Vicuna R, Barreiro-de-Acosta M, Juanola X, et al. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterol Hepatol. 2021;44:587\u201398. https:\/\/doi.org\/10.1016\/j.gastrohep.2021.01.007.","journal-title":"Gastroenterol Hepatol"},{"key":"2049_CR161","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.reumae.2021.06.001","volume":"18","author":"CO Sanchez Gonzalez","year":"2022","unstructured":"Sanchez Gonzalez CO, Nieto Gonzalez JC. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature. Reumatol Clin (Engl Ed). 2022;18:453\u20138. https:\/\/doi.org\/10.1016\/j.reumae.2021.06.001.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2049_CR162","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00296-017-3694-5","volume":"37","author":"O Barrett","year":"2017","unstructured":"Barrett O, Abramovich E, Dreiher J, Novack V, Abu-Shakra M. Short- and long-term mortality due to sepsis in patients with rheumatoid arthritis. Rheumatol Int. 2017;37:1021\u20136. https:\/\/doi.org\/10.1007\/s00296-017-3694-5.","journal-title":"Rheumatol Int"},{"key":"2049_CR163","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1177\/0885066620917588","volume":"36","author":"M Krasselt","year":"2021","unstructured":"Krasselt M, Baerwald C, Petros S, Seifert O. Mortality of sepsis in patients with rheumatoid arthritis: a single-center retrospective analysis and comparison with a control group. J Intensive Care Med. 2021;36:766\u201374. https:\/\/doi.org\/10.1177\/0885066620917588.","journal-title":"J Intensive Care Med"},{"key":"2049_CR164","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/mr\/roac088","volume":"33","author":"S Mori","year":"2023","unstructured":"Mori S, Ueki Y, Miyamura T, Ishii K, Hidaka T, Yoshitama T, et al. Outcomes and risk factors for mortality in Pneumocystis pneumonia patients with rheumatoid arthritis: a multicentre retrospective cohort study. Mod Rheumatol. 2023;33:723\u201331. https:\/\/doi.org\/10.1093\/mr\/roac088.","journal-title":"Mod Rheumatol"},{"key":"2049_CR165","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003946","author":"YK Song","year":"2024","unstructured":"Song YK, Lee J, Jo J, Kwon JW. Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-003946.","journal-title":"RMD Open"},{"key":"2049_CR166","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41927-023-00354-7","volume":"7","author":"L Theander","year":"2023","unstructured":"Theander L, Jacobsson LTH, Turesson C. Osteoporosis-related fractures in men and women with established and early rheumatoid arthritis: predictors and risk compared with the general population. BMC Rheumatol. 2023;7:28. https:\/\/doi.org\/10.1186\/s41927-023-00354-7.","journal-title":"BMC Rheumatol"},{"key":"2049_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158740","author":"P Pietschmann","year":"2022","unstructured":"Pietschmann P, Butylina M, Kerschan-Schindl K, Sipos W. Mechanisms of systemic osteoporosis in rheumatoid arthritis. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23158740.","journal-title":"Int J Mol Sci"},{"key":"2049_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041138","author":"T Miyamoto","year":"2025","unstructured":"Miyamoto T. Osteoporosis and rheumatoid arthritis: mechanisms underlying osteoclast differentiation and activation or factors associated with hip fractures. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14041138.","journal-title":"J Clin Med"},{"key":"2049_CR169","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10067-024-06932-5","volume":"43","author":"N Gupta","year":"2024","unstructured":"Gupta N, Kanwar N, Arora A, Khatri K, Kanwal A. The interplay of rheumatoid arthritis and osteoporosis: exploring the pathogenesis and pharmacological approaches. Clin Rheumatol. 2024;43:1421\u201333. https:\/\/doi.org\/10.1007\/s10067-024-06932-5.","journal-title":"Clin Rheumatol"},{"key":"2049_CR170","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1007\/s00296-011-2175-5","volume":"32","author":"S Xu","year":"2012","unstructured":"Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int. 2012;32:3397\u2013403. https:\/\/doi.org\/10.1007\/s00296-011-2175-5.","journal-title":"Rheumatol Int"},{"key":"2049_CR171","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.6003","author":"SN Morin","year":"2025","unstructured":"Morin SN, Leslie WD, Schousboe JT. Osteoporosis: a review. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2025.6003.","journal-title":"JAMA"},{"key":"2049_CR172","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-025-03604-w","volume":"27","author":"G Yue","year":"2025","unstructured":"Yue G, Yan Y, Zeng X, Liu R, He T, Liu Y. Association between rheumatoid arthritis and kidney stones: a cross-sectional study of NHANES 2007\u20132020. Arthritis Res Ther. 2025;27:141. https:\/\/doi.org\/10.1186\/s13075-025-03604-w.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR173","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11255-019-02346-4","volume":"52","author":"S Raksasuk","year":"2020","unstructured":"Raksasuk S, Ungprasert P. Patients with rheumatoid arthritis have an increased risk of incident chronic kidney disease: a systematic review and meta-analysis of cohort studies. Int Urol Nephrol. 2020;52:147\u201354. https:\/\/doi.org\/10.1007\/s11255-019-02346-4.","journal-title":"Int Urol Nephrol"},{"key":"2049_CR174","doi-asserted-by":"publisher","first-page":"481","DOI":"10.5114\/reum\/177005","volume":"61","author":"KM Tyczynska","year":"2023","unstructured":"Tyczynska KM, Augustyniak-Bartosik H, Swierkot J. Rheumatoid arthritis - medication dosage in chronic kidney disease. Reumatologia. 2023;61:481\u201391. https:\/\/doi.org\/10.5114\/reum\/177005.","journal-title":"Reumatologia"},{"key":"2049_CR175","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/hon.2525","volume":"36","author":"A Klein","year":"2018","unstructured":"Klein A, Polliack A, Gafter-Gvili A. Rheumatoid arthritis and lymphoma: incidence, pathogenesis, biology, and outcome. Hematol Oncol. 2018;36:733\u20139. https:\/\/doi.org\/10.1002\/hon.2525.","journal-title":"Hematol Oncol"},{"key":"2049_CR176","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3816\/CLM.2008.n.009","volume":"8","author":"R Kaiser","year":"2008","unstructured":"Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma. 2008;8:87\u201393. https:\/\/doi.org\/10.3816\/CLM.2008.n.009.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2049_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60071156","author":"AA Imam","year":"2024","unstructured":"Imam AA. Anti-TNF alpha and risk of lymphoma in rheumatoid arthritis: a systematic review and meta-analysis. Medicina Kaunas. 2024. https:\/\/doi.org\/10.3390\/medicina60071156.","journal-title":"Medicina Kaunas"},{"key":"2049_CR178","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/s0049-0172(97)80023-6","volume":"26","author":"L Georgescu","year":"1997","unstructured":"Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26:794\u2013804. https:\/\/doi.org\/10.1016\/s0049-0172(97)80023-6.","journal-title":"Semin Arthritis Rheum"},{"key":"2049_CR179","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2005.01.007","volume":"34","author":"A Ekbom","year":"2005","unstructured":"Ekbom A. Epidemiology of lymphoma development in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2005;34:28\u201330. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.007.","journal-title":"Semin Arthritis Rheum"},{"key":"2049_CR180","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/acr.25356","volume":"76","author":"JC Janak","year":"2024","unstructured":"Janak JC, Ross RD, Brady BL, Palmer L, Howard JT, Baker JF. Prevalence of cardiovascular and cancer risk factors among rheumatoid arthritis patients prescribed JAK inhibitors and tumor necrosis factor inhibitors: a cross-sectional study. Arthritis Care Res (Hoboken). 2024;76:1287\u201393. https:\/\/doi.org\/10.1002\/acr.25356.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2049_CR181","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1093\/rheumatology\/keaf092","volume":"64","author":"S Ahmed","year":"2025","unstructured":"Ahmed S, Pfeiffer RM, Jackson SS, Song M, Mariette X, Seror R, et al. Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. Rheumatology (Oxford). 2025;64:4172\u201380. https:\/\/doi.org\/10.1093\/rheumatology\/keaf092.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/ar2904","volume":"12","author":"A Strangfeld","year":"2010","unstructured":"Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12:R5. https:\/\/doi.org\/10.1186\/ar2904.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR183","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/ard-2024-225981","volume":"84","author":"E Sebbag","year":"2025","unstructured":"Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, Askling J, Gente K, et al. Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis. 2025;84:643\u201352. https:\/\/doi.org\/10.1136\/ard-2024-225981.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR184","doi-asserted-by":"publisher","unstructured":"Sebbag E, Lauper K, Molina-Collada J, Aletaha D, Askling J, Gente K, Bertheussen H, Bitoun S, Bolek EC, Burmester GR, Canhao HM, Chatzidionysiou K, Curtis JR, Danlos FX, Guimaraes V, Hetland ML, Iannone F, Kostine M, Kragstrup TW, Kvien TK, Regierer AC, Schulze-Koops H, Silva-Fernandez L, Szekanecz Z, Buch MH, Finckh A, Gottenberg JE. 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis. 2024. https:\/\/doi.org\/10.1136\/ard-2024-225982","DOI":"10.1136\/ard-2024-225982"},{"key":"2049_CR185","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","volume":"84","author":"P Nash","year":"2025","unstructured":"Nash P, Kerschbaumer A, Konzett V, Aletaha D, Dorner T, Fleischmann R, et al. Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update. Ann Rheum Dis. 2025;84:664\u201379. https:\/\/doi.org\/10.1016\/j.ard.2025.01.032.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR186","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/rheumatology\/key165","volume":"58","author":"C Lahaye","year":"2019","unstructured":"Lahaye C, Tatar Z, Dubost JJ, Tournadre A, Soubrier M. Management of inflammatory rheumatic conditions in the elderly. Rheumatology (Oxford). 2019;58:748\u201364. https:\/\/doi.org\/10.1093\/rheumatology\/key165.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR187","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-024-01466-0","volume":"64","author":"NN Ngcobo","year":"2025","unstructured":"Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clin Pharmacokinet. 2025;64:335\u201367. https:\/\/doi.org\/10.1007\/s40262-024-01466-0.","journal-title":"Clin Pharmacokinet"},{"key":"2049_CR188","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3928\/02793695-20090902-06","volume":"47","author":"RH Howland","year":"2009","unstructured":"Howland RH. Effects of aging on pharmacokinetic and pharmacodynamic drug processes. J Psychosoc Nurs Ment Health Serv. 2009;47:15\u20136. https:\/\/doi.org\/10.3928\/02793695-20090902-06.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"2049_CR189","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2165\/00003088-198815050-00002","volume":"15","author":"KW Woodhouse","year":"1988","unstructured":"Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet. 1988;15:287\u201394. https:\/\/doi.org\/10.2165\/00003088-198815050-00002.","journal-title":"Clin Pharmacokinet"},{"key":"2049_CR190","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3109\/00498254.2014.932470","volume":"44","author":"M Subramanian","year":"2014","unstructured":"Subramanian M, Kurawattimath V, Pocha K, Freeden C, Rao I, Mariappan TT, et al. Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. Xenobiotica. 2014;44:1108\u201316. https:\/\/doi.org\/10.3109\/00498254.2014.932470.","journal-title":"Xenobiotica"},{"key":"2049_CR191","first-page":"1903","volume":"24","author":"F Bressolle","year":"1997","unstructured":"Bressolle F, Bologna C, Kinowski JM, Arcos B, Sany J, Combe B. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol. 1997;24:1903\u20139.","journal-title":"J Rheumatol"},{"key":"2049_CR192","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2165\/11588280-000000000-00000","volume":"28","author":"A Corsonello","year":"2011","unstructured":"Corsonello A, Pedone C, Lattanzio F, Onder G, Antonelli Incalzi R, Gruppo Italiano di Farmacovigilanza nA. Association between glomerular filtration rate and adverse drug reactions in elderly hospitalized patients: the role of the estimating equation. Drugs Aging. 2011;28:379\u201390. https:\/\/doi.org\/10.2165\/11588280-000000000-00000.","journal-title":"Drugs Aging"},{"key":"2049_CR193","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0218","author":"HC Kwon","year":"2023","unstructured":"Kwon HC, Kang MI, Kim SM. Cystatin C as a predictor of renal function and methotrexate-associated toxicities in patients with rheumatoid arthritis. J Rheumatol. 2023. https:\/\/doi.org\/10.3899\/jrheum.2023-0218.","journal-title":"J Rheumatol"},{"key":"2049_CR194","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/14397595.2015.1088620","volume":"26","author":"K Saisho","year":"2016","unstructured":"Saisho K, Yoshikawa N, Sugata K, Hamada H, Tohma S. Prevalence of chronic kidney disease and administration of RA-related drugs in patients with RA: the NinJa 2012 study in Japan. Mod Rheumatol. 2016;26:331\u20135. https:\/\/doi.org\/10.3109\/14397595.2015.1088620.","journal-title":"Mod Rheumatol"},{"key":"2049_CR195","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/msc.112","volume":"5","author":"GJ Treharne","year":"2007","unstructured":"Treharne GJ, Douglas KM, Iwaszko J, Panoulas VF, Hale ED, Mitton DL, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care. 2007;5:175\u201390. https:\/\/doi.org\/10.1002\/msc.112.","journal-title":"Musculoskeletal Care"},{"key":"2049_CR196","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s10067-023-06646-0","volume":"42","author":"H Miyake","year":"2023","unstructured":"Miyake H, Sada RM, Akebo H, Tsugihashi Y, Hatta K. Prevalence and factors associated with polypharmacy among patients with rheumatoid arthritis: a single-centre, cross-sectional study. Clin Rheumatol. 2023;42:2287\u201395. https:\/\/doi.org\/10.1007\/s10067-023-06646-0.","journal-title":"Clin Rheumatol"},{"key":"2049_CR197","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.573542","volume":"7","author":"JD Jack","year":"2020","unstructured":"Jack JD, McCutchan R, Maier S, Schirmer M. Polypharmacy in middle-European rheumatoid arthritis-patients: a retrospective longitudinal cohort analysis with systematic literature review. Front Med Lausanne. 2020;7:573542. https:\/\/doi.org\/10.3389\/fmed.2020.573542.","journal-title":"Front Med Lausanne"},{"key":"2049_CR198","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0897190019869158","volume":"34","author":"APM Gomides","year":"2021","unstructured":"Gomides APM, Albuquerque CP, Santos ABV, Amorim RBC, Bertolo MB, Junior PL, et al. High levels of polypharmacy in rheumatoid arthritis-a challenge not covered by current management recommendations: data from a large real-life study. J Pharm Pract. 2021;34:365\u201371. https:\/\/doi.org\/10.1177\/0897190019869158.","journal-title":"J Pharm Pract"},{"key":"2049_CR199","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00296-025-05804-8","volume":"45","author":"W Berthelot","year":"2025","unstructured":"Berthelot W, Sirois C, Julien AS, Amiable N, Bessette L, Desaulniers P, et al. The association between polypharmacy and disease control in rheumatoid arthritis and systemic lupus erythematosus: a cohort study. Rheumatol Int. 2025;45:44. https:\/\/doi.org\/10.1007\/s00296-025-05804-8.","journal-title":"Rheumatol Int"},{"key":"2049_CR200","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70066","volume":"7","author":"S Benamar","year":"2025","unstructured":"Benamar S, Lukas C, Daien C, Gaujoux-Viala C, Gossec L, Rat AC, et al. Polypharmacy in early rheumatoid arthritis: impact on treatment response and adverse event risk in a multicenter French prospective cohort study. ACR Open Rheumatol. 2025;7:e70066. https:\/\/doi.org\/10.1002\/acr2.70066.","journal-title":"ACR Open Rheumatol"},{"key":"2049_CR201","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/rheumatology\/kez037","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, et al. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2019;58:1767\u201376. https:\/\/doi.org\/10.1093\/rheumatology\/kez037.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR202","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-025-03551-6","volume":"27","author":"K Khoroshun","year":"2025","unstructured":"Khoroshun K, Bantel C, Hoffmann F, Jobski K. Methotrexate-related drug reactions on kidneys and liver in rheumatoid arthritis: an analysis of spontaneous reports in EudraVigilance. Arthritis Res Ther. 2025;27:80. https:\/\/doi.org\/10.1186\/s13075-025-03551-6.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR203","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40360-024-00738-6","volume":"25","author":"T Honma","year":"2024","unstructured":"Honma T, Onda K, Masuyama K. Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use. BMC Pharmacol Toxicol. 2024;25:13. https:\/\/doi.org\/10.1186\/s40360-024-00738-6.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2049_CR204","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40744-020-00275-8","volume":"8","author":"A Walton","year":"2021","unstructured":"Walton A, Paik J, Quebe A, Kannowski CL, Choong C, Anderson S, et al. Frequency of prescription claims for drugs that may interact with Janus kinase inhibitors among patients with rheumatoid arthritis in the US. Rheumatol Ther. 2021;8:599\u2013607. https:\/\/doi.org\/10.1007\/s40744-020-00275-8.","journal-title":"Rheumatol Ther"},{"key":"2049_CR205","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/17425255.2024.2373092","volume":"20","author":"S Chandrashekara","year":"2024","unstructured":"Chandrashekara S. Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2024;20:741\u20138. https:\/\/doi.org\/10.1080\/17425255.2024.2373092.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2049_CR206","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/BOR.0000000000000281","volume":"28","author":"MA Friedman","year":"2016","unstructured":"Friedman MA, Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016;28:330\u20136. https:\/\/doi.org\/10.1097\/BOR.0000000000000281.","journal-title":"Curr Opin Rheumatol"},{"key":"2049_CR207","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40266-025-01195-4","volume":"42","author":"M Harigai","year":"2025","unstructured":"Harigai M, Sugihara T. Management of late-onset rheumatoid arthritis with treat-to-target strategy. Drugs Aging. 2025;42:413\u201333. https:\/\/doi.org\/10.1007\/s40266-025-01195-4.","journal-title":"Drugs Aging"},{"key":"2049_CR208","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00296-025-05908-1","volume":"45","author":"O Zimba","year":"2025","unstructured":"Zimba O, Baimukhamedov C, Kocyigit BF. Late-onset rheumatoid arthritis: clinical features, diagnostic challenges, and treatment approaches. Rheumatol Int. 2025;45:152. https:\/\/doi.org\/10.1007\/s00296-025-05908-1.","journal-title":"Rheumatol Int"},{"key":"2049_CR209","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247594","author":"S Takanashi","year":"2024","unstructured":"Takanashi S, Kaneko Y. Unmet needs and current challenges of rheumatoid arthritis: difficult-to-treat rheumatoid arthritis and late-onset rheumatoid arthritis. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13247594.","journal-title":"J Clin Med"},{"key":"2049_CR210","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70013","volume":"7","author":"J Lee","year":"2025","unstructured":"Lee J, Martindale J, Wallace BI, Singh N, Makris UE, Bynum JPW. Changes in long-term glucocorticoid use among older adults after new diagnosis of late-onset rheumatoid arthritis. ACR Open Rheumatol. 2025;7:e70013. https:\/\/doi.org\/10.1002\/acr2.70013.","journal-title":"ACR Open Rheumatol"},{"key":"2049_CR211","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/mr\/roae011","volume":"34","author":"M Kojima","year":"2024","unstructured":"Kojima M, Sugihara T, Kawahito Y, Kojima T, Kaneko Y, Ishikawa H, et al. Consensus statement on the management of late-onset rheumatoid arthritis. Mod Rheumatol. 2024;34:1095\u2013102. https:\/\/doi.org\/10.1093\/mr\/roae011.","journal-title":"Mod Rheumatol"},{"key":"2049_CR212","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/mr\/roae117","volume":"35","author":"C Baimukhamedov","year":"2025","unstructured":"Baimukhamedov C, Baimukhamedova M. Late-onset rheumatoid arthritis: justifying the need for international practice guidelines and classification criteria. Mod Rheumatol. 2025;35:597\u20138. https:\/\/doi.org\/10.1093\/mr\/roae117.","journal-title":"Mod Rheumatol"},{"key":"2049_CR213","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/mr\/roae027","volume":"34","author":"S Asai","year":"2024","unstructured":"Asai S, Suzuki M, Hara R, Hirano Y, Nagamine S, Kaneko T, et al. Comparison of effectiveness of methotrexate in patients with late-onset versus younger-onset rheumatoid arthritis: real-world data from an inception cohort in Japan (NICER-J). Mod Rheumatol. 2024;34:892\u20139. https:\/\/doi.org\/10.1093\/mr\/roae027.","journal-title":"Mod Rheumatol"},{"key":"2049_CR214","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/RHU.0000000000000296","volume":"21","author":"E Gvozdenovic","year":"2015","unstructured":"Gvozdenovic E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, et al. Assessment of global disease activity in rheumatoid arthritis by patients and physicians: differences across countries in the METEOR database. J Clin Rheumatol. 2015;21:349\u201354. https:\/\/doi.org\/10.1097\/RHU.0000000000000296.","journal-title":"J Clin Rheumatol"},{"key":"2049_CR215","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3899\/jrheum.171176","volume":"45","author":"SA Bergstra","year":"2018","unstructured":"Bergstra SA, Allaart CF, Ramiro S, Chopra A, Govind N, Silva C, et al. Sex-associated treatment differences and their outcomes in rheumatoid arthritis: results from the METEOR register. J Rheumatol. 2018;45:1361\u20136. https:\/\/doi.org\/10.3899\/jrheum.171176.","journal-title":"J Rheumatol"},{"key":"2049_CR216","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001203","author":"SA Bergstra","year":"2020","unstructured":"Bergstra SA, Allaart CF, Vega-Morales D, De Buck M, Murphy E, Salomon Escoto K, et al. Body mass index and treatment survival in patients with RA starting treatment with TNF\u03b1-inhibitors: long-term follow-up in the real-life METEOR registry. RMD Open. 2020. https:\/\/doi.org\/10.1136\/rmdopen-2020-001203.","journal-title":"RMD Open"},{"key":"2049_CR217","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/rheumatology\/keab389","volume":"61","author":"M Dey","year":"2022","unstructured":"Dey M, Zhao SS, Moots RJ, Bergstra SA, Landewe RB, Goodson NJ. The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database. Rheumatology (Oxford). 2022;61:713\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/keab389.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.07.005","author":"C Triaille","year":"2025","unstructured":"Triaille C, Durez P, Smolen JS, McInnes IB, Lauwerys B, Limaye N. Precision medicine and the chaos theory in rheumatoid arthritis. Ann Rheum Dis. 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.07.005.","journal-title":"Ann Rheum Dis"},{"key":"2049_CR219","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70239","volume":"28","author":"S Kubo","year":"2025","unstructured":"Kubo S, Tanaka Y. Pursuing precision medicine in managing rheumatoid arthritis. Int J Rheum Dis. 2025;28:e70239. https:\/\/doi.org\/10.1111\/1756-185X.70239.","journal-title":"Int J Rheum Dis"},{"key":"2049_CR220","first-page":"225","volume":"1","author":"RP Torres","year":"2022","unstructured":"Torres RP, Santos FP, Branco JC. Methotrexate: implications of pharmacogenetics in the treatment of patients with rheumatoid arthritis. ARP Rheumatol. 2022;1:225\u20139.","journal-title":"ARP Rheumatol"},{"key":"2049_CR221","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/17425255.2020.1777279","volume":"16","author":"B Szostak","year":"2020","unstructured":"Szostak B, Machaj F, Rosik J, Pawlik A. Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients. Expert Opin Drug Metab Toxicol. 2020;16:617\u201326. https:\/\/doi.org\/10.1080\/17425255.2020.1777279.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2049_CR222","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2217\/pgs-2020-0043","volume":"21","author":"SS Gilani","year":"2020","unstructured":"Gilani SS, Nair N, Plant D, Hyrich K, Morgan AW, Morris AP, et al. Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. Pharmacogenomics. 2020;21:1151\u20136. https:\/\/doi.org\/10.2217\/pgs-2020-0043.","journal-title":"Pharmacogenomics"},{"key":"2049_CR223","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/978-1-0716-2573-6_19","volume":"2547","author":"A Aluko","year":"2022","unstructured":"Aluko A, Ranganathan P. Pharmacogenetics of drug therapies in rheumatoid arthritis. Methods Mol Biol. 2022;2547:527\u201367. https:\/\/doi.org\/10.1007\/978-1-0716-2573-6_19.","journal-title":"Methods Mol Biol"},{"key":"2049_CR224","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/art.42764","volume":"76","author":"SW Syversen","year":"2024","unstructured":"Syversen SW, Gehin JE, Goll GL, Bolstad N, Haavardsholm EA, Lillegraven S. Therapeutic drug monitoring: a tool to optimize treatment of inflammatory joint diseases. Arthritis Rheum. 2024;76:667\u20139. https:\/\/doi.org\/10.1002\/art.42764.","journal-title":"Arthritis Rheum"},{"key":"2049_CR225","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-079830","volume":"387","author":"L Kawano-Dourado","year":"2024","unstructured":"Kawano-Dourado L, Kristianslund EK, Zeraatkar D, Jani M, Makharia G, Hazlewood G, et al. Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline. BMJ. 2024;387:e079830. https:\/\/doi.org\/10.1136\/bmj-2024-079830.","journal-title":"BMJ"},{"key":"2049_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-025-01628-8","author":"P Hu","year":"2025","unstructured":"Hu P, Lee EK, Li Q, Tam LS, Wong SY, Poon PK, et al. Mediterranean diet and rheumatoid arthritis: a nine-year cohort study and systematic review with meta-analysis. Eur J Clin Nutr. 2025. https:\/\/doi.org\/10.1038\/s41430-025-01628-8.","journal-title":"Eur J Clin Nutr"},{"key":"2049_CR227","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jand.2024.07.009","volume":"124","author":"K Malani","year":"2024","unstructured":"Malani K, Pradhan S, Madani MM, Roberts MB, Shadyab A, Allison M, et al. Association of diet quality with risk of incident rheumatoid arthritis in the Women\u2019s Health Initiative. J Acad Nutr Diet. 2024;124:1451\u201373. https:\/\/doi.org\/10.1016\/j.jand.2024.07.009.","journal-title":"J Acad Nutr Diet"},{"key":"2049_CR228","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03543-6","volume":"27","author":"TJ van Wesemael","year":"2025","unstructured":"van Wesemael TJ, Morton FR, Heutz JW, Maurits MP, Dorjee AL, Porter D, et al. Smoking as a risk factor for rheumatoid arthritis: predominant association with IgA autoantibodies - comprehensive analysis of anti-modified protein antibodies with smoking and genetic risk factors in rheumatoid arthritis. Arthritis Res Ther. 2025;27:101. https:\/\/doi.org\/10.1186\/s13075-025-03543-6.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR229","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1038\/s41598-024-61950-2","volume":"14","author":"X Qi","year":"2024","unstructured":"Qi X, Fu J, Liu J, Wu X, Zheng X, Wang S. Association between secondhand smoke exposure and rheumatoid arthritis in US never-smoking adults: a cross-sectional study from NHANES. Sci Rep. 2024;14:11061. https:\/\/doi.org\/10.1038\/s41598-024-61950-2.","journal-title":"Sci Rep"},{"key":"2049_CR230","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5114\/reum\/199933","volume":"63","author":"Z Apostolova","year":"2025","unstructured":"Apostolova Z, Shivacheva T, Georgiev T. Impact of comorbidities, diabetes, and smoking on sustained outcomes in rheumatoid arthritis: a retrospective study. Reumatologia. 2025;63:97\u2013103. https:\/\/doi.org\/10.5114\/reum\/199933.","journal-title":"Reumatologia"},{"key":"2049_CR231","doi-asserted-by":"publisher","DOI":"10.3390\/nu13072231","author":"H VanEvery","year":"2021","unstructured":"VanEvery H, Yang W, Olsen N, Bao L, Lu B, Wu S, et al. Alcohol consumption and risk of rheumatoid arthritis among Chinese adults: a prospective study. Nutrients. 2021. https:\/\/doi.org\/10.3390\/nu13072231.","journal-title":"Nutrients"},{"issue":"1","key":"2049_CR232","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1097\/EDE.0000000000000732","volume":"28","author":"CR Jung","year":"2017","unstructured":"Jung CR, Hsieh HY, Hwang BF. Air pollution as a potential determinant of rheumatoid arthritis: a population-based cohort study in Taiwan. Epidemiology. 2017;28(1):S54\u20139. https:\/\/doi.org\/10.1097\/EDE.0000000000000732.","journal-title":"Epidemiology"},{"key":"2049_CR233","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.semarthrit.2019.10.005","volume":"50","author":"D Di","year":"2020","unstructured":"Di D, Zhang L, Wu X, Leng R. Long-term exposure to outdoor air pollution and the risk of development of rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50:266\u201375. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.10.005.","journal-title":"Semin Arthritis Rheum"},{"key":"2049_CR234","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1093\/rheumatology\/keab049","volume":"60","author":"G Adami","year":"2021","unstructured":"Adami G, Viapiana O, Rossini M, Orsolini G, Bertoldo E, Giollo A, et al. Association between environmental air pollution and rheumatoid arthritis flares. Rheumatology (Oxford). 2021;60:4591\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keab049.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.118557","volume":"302","author":"BB Feng","year":"2025","unstructured":"Feng BB, Zhang YX, Dai XY, Nie MQ, Liu YY, Ma RW, et al. Association of ambient air pollution with incident rheumatoid arthritis, subsequent respiratory diseases, and death: a multi-state analysis of a prospective cohort. Ecotoxicol Environ Saf. 2025;302:118557. https:\/\/doi.org\/10.1016\/j.ecoenv.2025.118557.","journal-title":"Ecotoxicol Environ Saf"},{"key":"2049_CR236","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glad213","author":"N Mukherjee","year":"2024","unstructured":"Mukherjee N, Harrison TC. Epigenetic aging and rheumatoid arthritis. J Gerontol A Biol Sci Med Sci. 2024. https:\/\/doi.org\/10.1093\/gerona\/glad213.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2049_CR237","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-025-01919-8","volume":"17","author":"Y Ou","year":"2025","unstructured":"Ou Y, Wang Z, Yuan Y, He Y, Li W, Ren H, et al. Epigenetic age acceleration and rheumatoid arthritis: an NHANES-based analysis and survival prediction models. Clin Epigenetics. 2025;17:111. https:\/\/doi.org\/10.1186\/s13148-025-01919-8.","journal-title":"Clin Epigenetics"},{"key":"2049_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2025.102038","volume":"42","author":"J Zhao","year":"2025","unstructured":"Zhao J, Li Y, Zhang R, Shan Y, Song C, Cheng Y, et al. Therapeutic gene targets and epigenetic modifications in rheumatoid arthritis: insights from MTX, JAK inhibitors, and LLDT-8. Biochemistry and Biophysics Reports. 2025;42:102038. https:\/\/doi.org\/10.1016\/j.bbrep.2025.102038.","journal-title":"Biochemistry and Biophysics Reports"},{"key":"2049_CR239","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224632","volume":"14","author":"V Panga","year":"2019","unstructured":"Panga V, Kallor AA, Nair A, Harshan S, Raghunathan S. Mitochondrial dysfunction in rheumatoid arthritis: a comprehensive analysis by integrating gene expression, protein-protein interactions and gene ontology data. PLoS One. 2019;14:e0224632. https:\/\/doi.org\/10.1371\/journal.pone.0224632.","journal-title":"PLoS One"},{"key":"2049_CR240","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-023-03065-z","volume":"25","author":"DR Moellering","year":"2023","unstructured":"Moellering DR, Smith-Johnston K, Kelley C, Sammy MJ, Benedict J, Brock G, et al. Association between skeletal muscle mitochondrial dysfunction and insulin resistance in patients with rheumatoid arthritis: a case-control study. Arthritis Res Ther. 2023;25:85. https:\/\/doi.org\/10.1186\/s13075-023-03065-z.","journal-title":"Arthritis Res Ther"},{"key":"2049_CR241","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11061151","author":"MJ Lopez-Armada","year":"2022","unstructured":"Lopez-Armada MJ, Fernandez-Rodriguez JA, Blanco FJ. Mitochondrial dysfunction and oxidative stress in rheumatoid arthritis. Antioxidants (Basel). 2022. https:\/\/doi.org\/10.3390\/antiox11061151.","journal-title":"Antioxidants (Basel)"},{"key":"2049_CR242","doi-asserted-by":"publisher","first-page":"11631","DOI":"10.2147\/JIR.S499473","volume":"17","author":"P Li","year":"2024","unstructured":"Li P, Zhou M, Wang J, Tian J, Zhang L, Wei Y, et al. Important role of mitochondrial dysfunction in immune triggering and inflammatory response in rheumatoid arthritis. J Inflamm Res. 2024;17:11631\u201357. https:\/\/doi.org\/10.2147\/JIR.S499473.","journal-title":"J Inflamm Res"},{"key":"2049_CR243","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.4025","volume":"42","author":"A Abbasifard","year":"2024","unstructured":"Abbasifard A, Solgi G, Khodadadi I, Doosti-Irani A, Tayebinia H, Fazaeli A. Peripheral blood mononuclear cells show markers of mitochondrial dysfunction in rheumatoid arthritis. Cell Biochem Funct. 2024;42:e4025. https:\/\/doi.org\/10.1002\/cbf.4025.","journal-title":"Cell Biochem Funct"},{"key":"2049_CR244","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0317364","volume":"20","author":"Y Ao","year":"2025","unstructured":"Ao Y, Lan Q, Yu T, Wang Z, Zhang J. Cellular senescence-associated genes in rheumatoid arthritis: identification and functional analysis. PLoS One. 2025;20:e0317364. https:\/\/doi.org\/10.1371\/journal.pone.0317364.","journal-title":"PLoS One"},{"key":"2049_CR245","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s13287-021-02453-z","volume":"12","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Lee WJ, Hwang SC, Choe Y, Kim S, Bok E, et al. Chronic inflammation-induced senescence impairs immunomodulatory properties of synovial fluid mesenchymal stem cells in rheumatoid arthritis. Stem Cell Res Ther. 2021;12:502. https:\/\/doi.org\/10.1186\/s13287-021-02453-z.","journal-title":"Stem Cell Res Ther"},{"key":"2049_CR246","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1007\/s10067-019-04615-0","volume":"38","author":"LE Petersen","year":"2019","unstructured":"Petersen LE, Schuch JB, de Azeredo LA, Baptista TSA, Motta JG, do Prado AD, et al. Characterization of senescence biomarkers in rheumatoid arthritis: relevance to disease progression. Clin Rheumatol. 2019;38:2909\u201315. https:\/\/doi.org\/10.1007\/s10067-019-04615-0.","journal-title":"Clin Rheumatol"},{"key":"2049_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156762","volume":"184","author":"F Xu","year":"2024","unstructured":"Xu F, Li Z, Liu T, Pang X, Fan C, Jiang H. The role of cellular senescence in the pathogenesis of rheumatoid arthritis: focus on IL-6 as a target gene. Cytokine. 2024;184:156762. https:\/\/doi.org\/10.1016\/j.cyto.2024.156762.","journal-title":"Cytokine"},{"key":"2049_CR248","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.55563\/clinexprheumatol\/exg1ic","volume":"40","author":"JT Ding","year":"2022","unstructured":"Ding JT, Hong FF, Yang SL. Roles of autophagy in rheumatoid arthritis. Clin Exp Rheumatol. 2022;40:2179\u201387. https:\/\/doi.org\/10.55563\/clinexprheumatol\/exg1ic.","journal-title":"Clin Exp Rheumatol"},{"key":"2049_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117734","volume":"254","author":"J Karami","year":"2020","unstructured":"Karami J, Masoumi M, Khorramdelazad H, Bashiri H, Darvishi P, Sereshki HA, et al. Role of autophagy in the pathogenesis of rheumatoid arthritis: latest evidence and therapeutic approaches. Life Sci. 2020;254:117734. https:\/\/doi.org\/10.1016\/j.lfs.2020.117734.","journal-title":"Life Sci"},{"key":"2049_CR250","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/keq298","volume":"50","author":"I Colmegna","year":"2011","unstructured":"Colmegna I, Weyand CM. Haematopoietic stem and progenitor cells in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:252\u201360. https:\/\/doi.org\/10.1093\/rheumatology\/keq298.","journal-title":"Rheumatology (Oxford)"},{"key":"2049_CR251","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.cell.2025.03.011","volume":"188","author":"G Kroemer","year":"2025","unstructured":"Kroemer G, Maier AB, Cuervo AM, Gladyshev VN, Ferrucci L, Gorbunova V, et al. From geroscience to precision geromedicine: understanding and managing aging. Cell. 2025;188:2043\u201362. https:\/\/doi.org\/10.1016\/j.cell.2025.03.011.","journal-title":"Cell"},{"key":"2049_CR252","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41591-023-02784-9","volume":"30","author":"M Moqri","year":"2024","unstructured":"Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, et al. Validation of biomarkers of aging. Nat Med. 2024;30:360\u201372. https:\/\/doi.org\/10.1038\/s41591-023-02784-9.","journal-title":"Nat Med"},{"key":"2049_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39786-7","volume":"14","author":"Y Rolland","year":"2023","unstructured":"Rolland Y, Sierra F, Ferrucci L, Barzilai N, De Cabo R, Mannick J, et al. Challenges in developing geroscience trials. Nat Commun. 2023;14:5038. https:\/\/doi.org\/10.1038\/s41467-023-39786-7.","journal-title":"Nat Commun"},{"key":"2049_CR254","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/RHU.0000000000000081","volume":"20","author":"B Haraoui","year":"2014","unstructured":"Haraoui B, Bensen W, Thorne C, Wade J, Deamude M, Prince J, et al. Treating rheumatoid arthritis to target: a Canadian patient survey. J Clin Rheumatol. 2014;20:61\u20137. https:\/\/doi.org\/10.1097\/RHU.0000000000000081.","journal-title":"J Clin Rheumatol"},{"key":"2049_CR255","doi-asserted-by":"crossref","unstructured":"Majnik J, Csaszar-Nagy N, Bocskei G, Bender T, Nagy G. Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis. Front Med (Lausanne). 2022;9:991677. 10.3389\/fmed.2022.991677\n.","DOI":"10.3389\/fmed.2022.991677"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02049-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-02049-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02049-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:38:59Z","timestamp":1773049139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-02049-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":255,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-02049-y","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"\u00a0Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"\u00a0Consent for publication"}},{"value":"Dr. Zoltan Ungvari serves as Editor-in-Chief for GeroScience. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}